EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study

Jingjing Lu, Xuelian Song, Chen Zhang, Yi Zhu, Huarui Yang, Yi Li

Frontiers in Oncology · 08.06.2026 · 16

DOI: 10.3389/fonc.2026.1737880 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Oncology, online erschienen am 08.06.2026. Verfasst von Jingjing Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PARP(Poly(ADP-ribose) polymerase) inhibitors are established as effective treatment for ovarian cancer; however, there have been no systematic studies of PARP inhibitor use in older patients with ovarian cancer.

Methods

This study was conducted at Peking University People’s Hospital. Archival data from patients with advanced age (≥ 65 years) with ovarian cancer between March 2018 and September 2023, who received olaparib or niraparib as maintenance therapy following either first-line platinum-based chemotherapy or platinum-sensitive recurrence (PSR) chemotherapy and achieved complete (CR) or partial response (PR). The two clinical scenarios (first-line maintenance and PSR maintenance) were analyzed separately.

Results

Of 56 included patients, 20 (35.7%) and 34 (60.7%) received olaparib and niraparib, respectively, while 2 (3.6%) switched from olaparib to niraparib due to intolerance. The mean age was 70.14 ± 4.63 years. Median progression-free survival (mPFS) was 24 months in 35 (62.5%) patients receiving PARP inhibitors as first-line maintenance therapy(1L-group). In the 1L group, CA125 level, whether CR was reached, BRCA mutation status, and R0 at initial surgery before PARP inhibitor therapy were associated with PFS in univariate analysis, and the latter three factors were independently associated with PFS on multivariate analysis. In the PSR group, among patients with PSR ≥12 months (n=13), mPFS was not reached; among those with PSR 6–12 months (n=7), mPFS was 9.6 months. Anemia (22.7%) was the most frequent grade 3–4 adverse event in the olaparib group, whereas thrombocytopenia (11.1%) was more common in the niraparib group. Both groups of patients experienced dose reduction, interruption, and discontinuation within the first 6 months. Niraparib had a lower termination rate than olaparib, and long-term PARP inhibitor use was generally well-tolerated.

Conclusions

PARP inhibitor (olaparib and niraparib) maintenance therapy yields favorable clinical outcomes for elderly ovarian cancer patients. Three clinical factors, attainment R0(no residual disease) after initial surgery, BRCA mutation, and CA-125 ≤10 U/mL before PARP inhibitor treatment, were predictive of longer PFS in elderly ovarian cancer patients undergoing first-line maintenance therapy with PARP inhibitors.

Schlagwörter

Stichwörter der Autor:innen

PARP inhibitorsmaintenance therapyolder adult patientsovarian cancerreal-world study

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China.
  • Department of Obstetrics and Gynecology, Handan Central Hospital, Handan, Hebei, China.

Zitieren

APA

Lu, J., Song, X., Zhang, C., Zhu, Y., Yang, H., & Li, Y. (2026). Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1737880

Vancouver

Lu J, Song X, Zhang C, Zhu Y, Yang H, Li Y. Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1737880

BibTeX
@article{Lu2026,
  author = {Lu, Jingjing and Song, Xuelian and Zhang, Chen and Zhu, Yi and Yang, Huarui and Li, Yi},
  title = {Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1737880}
}
Kostenlos starten →